Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafetinib in advanced solid tumors
NCT02717741Phase 1Unknown
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Start
- May 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tafetinib in solid tumor (advanced stage), sponsored by Nanjing Yoko Biomedical Co., Ltd. Primary endpoint: Dose-limiting toxicity at 3 weeks. Status: unknown.
02
Drugs
tafetinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02717741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717741.